TibaRay

About the offering

TibaRay is developing an ultra-fast, ultra-precise radiotherapy platform based on FLASH radiation technology—delivering cancer treatment in a fraction of a second instead of minutes, over 400x faster than today's state-of-the-art systems. FLASH radiobiology is a scientific discovery showing that ultra-rapid radiation can spare healthy tissue without compromising tumor kill, potentially allowing more curative treatments with dramatically reduced side effects, cost, and treatment time. The company has spent over a decade developing revolutionary linear accelerator and RF component technologies invented at Stanford University, with $27M+ invested including $14M+ in non-dilutive competitive federal grants. TibaRay holds 20+ issued and pending patents, operates a 24,000 sq ft fully integrated Silicon Valley facility (with radiation-shielded vault, CNC production, hydrogen brazing furnace, and ISO 13485-compliant QMS), and has secured its first commercial partnership through "TibaRay Inside™" with Leo Cancer Care, integrating its Galactica linac into Leo's treatment platform. The Wefunder campaign has raised $172,007 from 20+ investors, with a $605,000 featured investment from Tuoc Luong. The $9B global radiotherapy market is the initial target, with $20B+ in adjacent opportunities across cardiac arrhythmias, pulmonary emphysema, neurologic conditions, and other major illnesses. The Problem Approximately half of all cancer patients receive radiation therapy, yet current radiotherapy systems are slow (treatments take minutes per session), cause significant collateral damage to healthy tissue surrounding tumors, require dozens of treatment sessions over weeks, and are expensive to operate. The fundamental limitation is that conventional linear accelerators cannot deliver radiation fast enough to exploit the FLASH biological effect—the recently discovered phenomenon where ultra-rapid radiation delivery (in milliseconds rather than minutes) dramatically spares normal tissue while maintaining tumor-killing efficacy. This means patients currently endure unnecessary side effects, some tumors are deemed untreatable due to proximity to sensitive organs, and the high cost and long treatment timelines limit patient access globally. The $9B radiotherapy market has been growing at 6-8% CAGR but the underlying technology has not fundamentally changed in decades. The Solution TibaRay's PHASER platform makes conformal FLASH therapy clinically feasible for the first time by combining advances in accelerator physics, RF systems, and beam control developed over a decade of research originating at Stanford University. The system delivers therapeutic radiation in milliseconds rather than minutes, enabling the FLASH biological effect that spares healthy tissue without reducing tumor kill. This means: more curative treatments become possible (tumors near sensitive structures can be treated more aggressively), side effects are dramatically reduced, treatment time drops from weeks of daily sessions to potentially far fewer visits, twice as many patients can be treated per machine at reduced costs, and treatment becomes accessible to more patients globally. Near-term commercialization comes through the "TibaRay Inside™" strategy—selling Galactica linear accelerators as components integrated into partner treatment systems. The first commercial partnership is with Leo Cancer Care, which is integrating the Galactica linac into its complete treatment platform. Beyond cancer, FLASH radiation has potential applications in cardiac arrhythmias (ventricular tachycardia, atrial fibrillation), pulmonary emphysema, functional neurologic conditions, arthritis/inflammatory conditions, and potentially Alzheimer's—with first human clinical trials of focused radiotherapy for some of these already performed by the company's Chief Medical Advisor, Dr. Bill Loo. Business Model Near-term revenue comes from delivering linear accelerators into "TibaRay Inside™" markets including healthcare (Leo Cancer Care partnership), non-destructive testing, and border security applications—leveraging the same core accelerator technology across multiple verticals. The long-term objective is full commercialization and deployment of the PHASER system for FLASH radiotherapy, targeting multi-billion-dollar revenue opportunities across global cancer treatment and adjacent medical applications. The company's 24,000 sq ft fully integrated facility supports prototyping, testing, and production with radiation safety approval and ISO 13485 quality management compliance. Traction $27M+ invested in technology development over the past decade, including $14M+ in non-dilutive competitive federal grants. 20+ issued and pending patents protecting next-generation radiotherapy technology. First commercial partnership secured: TibaRay Inside™ with Leo Cancer Care (Galactica linac integrated into Leo's treatment platform). 24,000 sq ft fully integrated Silicon Valley facility operational with radiation-shielded vault, advanced production capabilities, and ISO 13485-compliant QMS. First human clinical trials of focused radiotherapy for non-cancer applications (cardiac, pulmonary) performed by co-founder Dr. Bill Loo. Featured in multiple publications. The Wefunder campaign has raised $172,007 from 20+ investors, with a $605,000 investment from featured investor Tuoc Luong (who articulated a three-part investment thesis around innovative technology/moat, societal benefit, and the CEO's proven track record of startup-to-IPO execution). No revenue figures were disclosed—the company appears to be in early commercialization with the Leo Cancer Care partnership as the first revenue-generating relationship. Team CEO and Director Thinh Tran is a Stanford graduate who founded Sigma Designs and grew it from startup to a NASDAQ-listed company with approximately $2B market cap, bringing 40+ years of leadership, capital-raising, and M&A experience. He also founded Vita Imaging. CTO, Co-Founder, and Director Sami Tantawi is an ASU Physics professor, former Stanford professor, and former SLAC (Stanford Linear Accelerator Center) chief scientist. He led world-class RF accelerator research, won the US Particle Accelerator School achievement award, and is an American Physical Society Fellow. Chief Medical Advisor, Co-Founder, and Director Bill Loo, MD, PhD is a Stanford Professor and Director of Thoracic Radiation Oncology, a global leader in lung cancer radiotherapy, FLASH therapy, and proton therapy, and co-inventor of PHASER. He has performed the first human clinical trials of focused radiotherapy for non-cancer applications.

FAQ